Fragile X Unplugged: Establishing Mobile EEG as the Next Frontier

January 21, 2026

A $100,000 FRAXA grant to Cincinnati Children’s Hospital is simplifying and testing EEG technology for home use, improving clinical trial accessibility and efficiency.

Read More »
Ziyuan Guo, PhD, and Lu Lu, PhD, standing together in a research lab with laboratory equipment in the background.

METTL3 Inhibitors and FDA-Approved Drugs in a New Fragile X Treatment Strategy Using Organoids

November 4, 2025

Researchers are testing METTL3 inhibitors and FDA-approved drugs in brain organoids to explore new pathways for treating Fragile X and related disorders.

Read More »

fNIRS to Measure Treatment Response in Young Children with Fragile X

February 13, 2024

The team tested functional near-infrared spectroscopy (fNIRS). fNIRS uses light sources and sensors on the scalp to build a heat map of the brain in action.

Read More »

Gene Therapy Translational Studies for Fragile X Syndrome

June 6, 2019

With FRAXA funding, researchers tested AAV gene therapy to restore FMRP in Fragile X mice, measuring safety, effectiveness, and brain activity to inform future trials.

Read More »

FXS Patients’ Social Deficits are Linked to Social Anxiety, Eye-tracking Study Says

February 4, 2019

Dr. Craig Erickson and colleagues at the University of Cincinnati used eye-tracking technology to understand sociability in Fragile X syndrome. This study affirms what so many parents, caretakers, and educators suspect: people with fragile X want to be social, and it is anxiety – not lack of interest – which usually hold them back. If anxiety could be reduced, more sociability would likely follow. Dr. Erickson is a Fragile X expert and FRAXA investigator who is currently conducting a Fragile X clinical trial of an investigational new drug.

Read More »
Craig Erickson, MD, Cincinnati Children's Hospital

Fragile X Clinical Trial of AZD7325 in Adults

February 1, 2018

FRAXA funded a trial of AZD7325, a drug that boosts GABA(A), in adults with Fragile X. Led by Dr. Craig Erickson, it also tested innovative biomarkers for future trials.

Read More »
Craig Erickson lab

Brain Imbalance Target of Dr. Erickson’s New Clinical Trial

October 25, 2017

Dr. Erickson’s trial targeted brain imbalance in Fragile X by boosting GABA signaling with AZD7325, aiming to restore excitatory–inhibitory balance and improve symptoms.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)